Results 21 to 30 of about 424,109 (164)

mRNA-1273 elicits higher NAb responses in treatment-naïve CLL vaccinees. [PDF]

, 2023
(A) ID50 neutralizing titers against the SARS-CoV-2 D614G and Delta variants in all CLL patients who received either the BNT162b2 or the mRNA-1273 vaccine.
Kai Qin (293713), Anju Bansal (56201), Randall S. Davis (8450517), Weimin Liu (50340), Sarah Sterrett (161415), Kazuhito Honjo (8450493), Victor M. Cruz Portillo (16469335), Benjamin M. Larimer (14928039), Mayur Narkhede (3826087), Regina M. Stoltz (16469317), Jeffrey R. Lancaster (1932982), Foluso J. Ogunsile (16469329), Paul A. Goepfert (7181315), Ellen R. Frederick (16469326), Allisa K. Oman (16469320), Rima B. Patel (16469332), Lucinda A. Hall (16469323), Ran Li (57928), Amitkumar Mehta (800257), Beatrice H. Hahn (8157399), Thomas J. Ketas (460721), Scott Sherrill-Mix (692150), Albert Cupo (409522)   +22 more
core   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Flow chart for 2-dose mRNA-1273 analysis cohort. [PDF]

, 2022
Flow chart for 2-dose mRNA-1273 analysis cohort.
Katia J. Bruxvoort (12476079), Yun Tian (411157), Hung Fu Tseng (12476097), Ana Florea (12476073), Gina S. Lee (12476085), Jennifer H. Ku (12476088), Yi Luo (143206), Lei Qian (292302), Bradley K. Ackerson (12476082), Julia E. Tubert (12476091), Lina S. Sy (12476076), Carla A. Talarico (12476094)   +11 more
core   +1 more source

Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave [PDF]

, 2023
Anti-SARS-CoV-2 vaccination of dialysis patients has been proven to be safe and effective to reduce COVID-19-related morbidity and mortality. However, data on the durability of anti-SARS-CoV-2 antibodies post-vaccination in peritoneal dialysis (PD ...
Robert Strassl, Andreas Vychytil, Florian Frommlet, Roman Reindl-Schwaighofer, Georg Beilhack, Rossella Monteforte   +5 more
core   +1 more source

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

Clinical Case Reports, 2022
In this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms.
Suresh Babu Chellapandian, Suha Turkmen, Imtiaz Salim, Shanmugavel Chinnakaruppan, Jassim Mohammad   +4 more
doaj   +1 more source

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Frontiers in Immunology, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson   +17 more
doaj   +1 more source

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.

PLoS Medicine, 2022
BackgroundMyocarditis and pericarditis following the Coronavirus Disease 2019 (COVID-19) mRNA vaccines administration have been reported, but their frequency is still uncertain in the younger population.
Marco Massari, Stefania Spila Alegiani, Cristina Morciano, Matteo Spuri, Pasquale Marchione, Patrizia Felicetti, Valeria Belleudi, Francesca Romana Poggi, Marco Lazzeretti, Michele Ercolanoni, Elena Clagnan, Emanuela Bovo, Gianluca Trifirò, Ugo Moretti, Giuseppe Monaco, Olivia Leoni, Roberto Da Cas, Fiorella Petronzelli, Loriana Tartaglia, Nadia Mores, Giovanna Zanoni, Paola Rossi, Sarah Samez, Cristina Zappetti, Anna Rosa Marra, Francesca Menniti Ippolito, TheShinISS-Vax|COVID Surveillance Group   +26 more
doaj   +1 more source

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions [PDF]

, 2023
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed.
Musk, Elon R, Cizmeci, Deniz, Collier, Ai-ris, Krammer, Florian, Dayal, Diana, Amanat, Fatima, Suscovich, Todd, Mann, Colin, Menon, Anil S, Kaplonek, Paulina, Nilles, Eric J, Rhee, Justin, Broge, Thomas, de St Aubin, Michael, Saphire, Erica Ollmann, Barouch, Dan H, Alter, Galit, Fischinger, Stephanie, Linde, Caitlyn, Lauffenburger, Douglas A   +19 more
core   +1 more source

Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis

Journal of the Formosan Medical Association, 2023
Background: Patients with chronic kidney disease are at high risk for coronavirus disease 2019. Little is known about immune response to severe acute respiratory syndrome coronavirus 2 vaccination in patients on peritoneal dialysis (PD).
Zhi-Ye Yu, Chun-Fu Lai, Tai-Shuan Lai, Shao-Yu Yang, Shih-I Chen, Mei-Jun Lai, Chun-Min Kang, Yu-Tsung Huang, Yi-Ting Chen, Po-Ren Hsueh, Yung-Ming Chen, Shuei-Liong Lin   +11 more
doaj   +1 more source